Physician profile
Bryan Contreras
NPI 1578549457
$7,609.87
in general payments reported to CMS, 2019-2025
34 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $418 · 2021: $1,236 · 2022: $1,318 · 2023: $1,467 · 2024: $1,636 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,040.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,444.17 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $706.76 | 2020-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $679.93 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $423.08 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.64 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $334.84 | 2021-2024 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $290.99 | 2019-2025 | |
| Qol Medical, LLC | $215.66 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $200.75 | 2022-2025 | Dupixent |
| Medtronic, INC. | $196.30 | 2021-2025 | Interstim, Pillcam |
| Ironwood Pharmaceuticals, INC | $179.50 | 2020-2024 | Linzess |
| Genzyme Corporation | $168.85 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $138.15 | 2019-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $137.03 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $128.23 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Gilead Sciences, INC. | $122.07 | 2021-2024 | |
| Ardelyx, INC. | $119.70 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $110.45 | 2019-2022 | |
| Ucb, INC. | $94.62 | 2019 | |
| Redhill Biopharma INC. | $85.02 | 2021-2023 | |
| Biocon Biologics INC | $65.02 | 2024-2025 | Hulio, Yesintek |
| Celltrion USA INC. | $45.40 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $35.38 | 2025 | Rezdiffra |
| Lilly USA, LLC | $34.00 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $31.56 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $30.83 | 2019-2021 | |
| Allergan, INC. | $22.73 | 2019 | |
| Teleflex LLC | $21.50 | 2024 | Solesta |
| Amgen INC. | $18.31 | 2023 | Avsola, Amjevita |
| Evoke Pharma, INC. | $14.37 | 2024 | |
| Janssen Scientific Affairs, LLC | $14.18 | 2022 | |
| Alfasigma USA, INC. | $13.70 | 2020 | |
| Capsovision, INC. | $13.15 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.